| Guojing Zhang,Yongye Liu,Chao Lin,Jianfei Guo,Long Xu,Junling Liu,Ying Piao,Guanzhong Zhang,Yuhui Liu,Yaling Han,Xiaodong Xie. Influence of tumor response on the survival of patients with extensive-stage small-cell lung cancer treated with the etoposide plus cisplatin chemotherapy regimen. Oncol Transl Med, 2015, 1: 65-68. |
| Influence of tumor response on the survival of patients with extensive-stage small-cell lung cancer treated with the etoposide plus cisplatin chemotherapy regimen |
| Received:January 12, 2015 Revised:February 04, 2015 |
| View Full Text View/Add Comment Download reader |
| KeyWord:extensive-stage small-cell lung cancer (ES-SCLC); tumor response; progression-free survival (PFS); overall survival (OS) |
| Author Name | Affiliation | E-mail | | Guojing Zhang | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | zhanggjing888@126.com | | Yongye Liu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | liuyongye666@163.com | | Chao Lin | Department of Gynaecology, The Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University, Wenzhou 325000, China | 185177989@qq.com | | Jianfei Guo | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | doctor_xxd@163.com | | Long Xu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | syysxh@yahoo.com.cn | | Junling Liu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | wawjljl870503@163.com | | Ying Piao | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | 15309880806@163.com | | Guanzhong Zhang | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | doctor_xxd@163.com | | Yuhui Liu | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | yalinghan2013@163.com | | Yaling Han | Department of Cardiology, Institute of Cardiovascular Research of PLA, The General Hospital of Shenyang Military Region, Shenyang 110840, China | yalinghan2013@163.com | | Xiaodong Xie | Department of Oncology, PLA cancer center, The General Hospital of Shenyang Military Region, Shenyang 110840, China | doctor_xxd@163.com |
|
| Hits: 7324 |
| Download times: 7446 |
| Abstract: |
| Objective?In this study, we evaluated the difference of progression-free survival (PFS) and overall survival (OS) between extensive-stage small-cell lung cancer (ES-SCLC) patients who acquired partial response (PR) or complete remission (CR) after two cycles of first-line chemotherapy with the etoposide plus cisplatin (EP) regimen and those who acquired PR or CR after four or six cycles.
Methods?A total of 106 eligible patients treated with the EP chemotherapy regimen for two to six cycles, at The General Hospital of Shenyang Military Region (China) between November 2004 and May 2011, were enrolled in this study. RECIST version 1.1 was used for the evaluation of chemotherapy efficiency. We followed up all eligible patients every 4 weeks. All statistical data were analyzed by using SPSS 21.0 statistical package for Windows.
Results?After a median follow-up of 293 days (range, 62–1531 days), all patients had died by the cutoff date. Fifty-one patients acquired PR or CR after two cycles of chemotherapy; the median PFS reached 6.0 months (95% CI, 5.1–6.9), and the median OS was 10.5 months (95% CI, 8.6–12.4). Twenty-eight patients acquired PR or CR after four or six cycles; the median PFS was 4.8 months (95% CI, 4.4–5.2), and the median OS was 7.5 months (95% CI, 6.8–8.2). Both PFS and OS showed a statistical difference between the two groups.
Conclusion?ES-SCLC patients who acquired PR or CR after two cycles of the EP regimen as first-line therapy had longer PFS and OS than those who acquired PR or CR after four or six cycles.
|
| Close |
|
|
|